inebilizumab NMOSD
Selected indexed studies
- International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab. (Neurol Neuroimmunol Neuroinflamm, 2023) [PMID:37258412]
- Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. (J Neurol, 2024) [PMID:37676297]
- Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. (Lancet, 2019) [PMID:31495497]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. (2019) pubmed
- Inebilizumab: First Approval. (2020) pubmed
- International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab. (2023) pubmed
- Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder. (2024) pubmed
- Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. (2024) pubmed
- Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. (2023) pubmed
- Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. (2021) pubmed
- Inebilizumab-cdon: USFDA Approved for the Treatment of NMOSD (Neuromyelitis Optica Spectrum Disorder). (2022) pubmed
- Advances in the long-term treatment of neuromyelitis optica spectrum disorder. (2024) pubmed
- PMID:38917254 (2024) pubmed